Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration for clinical trials in cancer patients. The new report, published this week by the international chemistry journal Angewandte Chemie, focuses on a compound called TIC10.
Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...
Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...